# Showstopper Re-evaluation Report

Run against the new chat strategy (Voyage `voyage-4-large` retrieval + Claude Haiku 4.5 with `temperature_override=0`) on 2026-05-23.

**Result: 10/10 of the 10 client-flagged showstoppers PASS** the regression criteria derived from the client's original feedback.

## Methodology

For each question:
1. Send the question (verbatim from the client's CSV) through the shim's `/aoai/history/generate` endpoint
2. Run automated checks that encode the client's original complaint — pass means we did **not** make the same mistake the client flagged
3. Each question may have multiple checks (e.g. positive: must mention the threshold; negative: must not invent drug elaborations)

All checks are heuristic (regex / keyword). They catch the specific failure patterns the client called out, but a clinical reviewer should still spot-check the full answers.

## Per-question results

### #1 — ✅ **PASS**
**Question:** Treatment for asymptomatic UTI in a pregnant patient

**Client's expected answer:** Treat after 2 cultures, nitrofurantoin, fosfomycin, cephalexin, amoxicillin

**Client's original complaint:** Did not clarify 2 consecutive cultures; invented Cephalexin description; merged SMX vs TMP

**Checks:**
- ✅ mentions 2 consecutive cultures
- ✅ no invented cephalexin elaboration
- ✅ SMX vs TMP distinction preserved

**Our new answer:**

> Asymptomatic bacteriuria in pregnancy requires treatment, unlike in non-pregnant populations [doc1].
> 
> Pregnant patients should be screened for asymptomatic bacteriuria early in pregnancy (weeks 12-16) and treated if confirmed on 2 consecutive cultures [doc1]. If left untreated, bacteriuria in pregnancy can progress to pyelonephritis and cause adverse fetal effects [doc1]. Antibiotic treatment reduces the incidence of pyelonephritis, preterm delivery rate, and risk of low birth-weight babies [doc1].
> 
> **Treatment options for asymptomatic bacteriuria in pregnancy include:** [doc2]
> - Amoxicillin (if organism is susceptible)
> - Amoxicillin/clavulanate
> - Cephalexin
> - Fosfomycin tromethamine (if organism is susceptible)
> - Nitrofurantoin (avoid near term due to risk of hemolytic anemia in fetus/newborn with G6PD deficiency, though this is rare)
> 
> **Agents to avoid in pregnancy:** [doc2]
> - Trimethoprim and sulfamethoxazole/trimethoprim in the first trimester (antifolate teratogenicity)
> - Sulfamethoxazole in the last 6 weeks (neonatal hyperbilirubinemia risk)
> - Fluoroquinolones (though animal data show cartilage effects, human data show no increased risk of major malformations)
> 
> **Follow-up:** Upon completion of therapy, perform a urine culture 1-2 weeks later, then monthly until delivery [doc2].

---

### #2 — ✅ **PASS**
**Question:** When should antibiotics be used in diverticular disease

**Client's expected answer:** Antibiotics no longer first-line for inflammatory process; guidelines do not support routine antibiotic use in uncomplicated disease

**Client's original complaint:** Blatantly wrong: "Antibiotics are used in the management of diverticular disease primarily for acute diverticulitis..."

**Checks:**
- ✅ acknowledges antibiotics not routine for uncomplicated diverticulitis
- ✅ does not say antibiotics are the default treatment

**Our new answer:**

> Antibiotics should be used selectively, rather than routinely, in acute diverticulitis, particularly for patients who are systemically unwell or have significant comorbidities.
> 
> Recent evidence has shifted away from routine antibiotic use in acute uncomplicated diverticulitis. [doc1] Multiple large randomized controlled trials—including the AVOD trial (623 patients) and DIABOLO trial (528 patients)—found no significant differences between antibiotic-treated and untreated groups in time to recovery, hospital stay duration, complications, or recurrence rates. [doc1] Long-term follow-up data extending 11 years showed no difference in complications, surgeries, or recurrence. [doc1] Systematic reviews and meta-analyses combining these trials with observational studies confirmed no significant differences in treatment failure, readmission, surgical intervention needs, or complications. [doc1]
> 
> The AGA, ASCRS, and NICE guidelines all recommend **selective use** of antibiotics based on individual patient factors. [doc1] Antibiotic therapy is appropriate specifically for patients who are **systemically unwell** (fever, severe left lower quadrant pain, peritonitis on examination, elevated white blood cell count), immunosuppressed, or have significant comorbidities. [doc1]
> 
> When antibiotics are indicated, they must cover gram-negative rods and anaerobes (particularly *Escherichia coli* and *Bacteroides fragilis*). [doc1] Typical outpatient regimens include a fluoroquinolone or sulfamethoxazole/trimethoprim combined with metronidazole, or amoxicillin/clavulanate alone, with treatment duration of 7–10 days. [doc1] Patients require clinical reassessment 2–3 days after initiation and weekly thereafter until complete symptom resolution. [doc1]
> 
> For **acute complicated diverticulitis** (with perforation, abscess, obstruction, or fistulization), inpatient admission with IV antibiotics and bowel rest is warranted. [doc1]

---

### #3 — ✅ **PASS**
**Question:** What is the dosage of oxybutynin to treat stress incontinence in an 85 yo female?

**Client's expected answer:** Oxybutynin is not a recommended therapy for stress incontinence

**Client's original complaint:** Information supplied was for urgency incontinence, not stress; dementia risk omitted

**Checks:**
- ✅ clarifies oxybutynin not indicated for stress incontinence
- ✅ does not give plain oxybutynin dose without stress-vs-urgency caveat

**Our new answer:**

> Oxybutynin is not indicated for stress incontinence; it is used for urgency incontinence and should be avoided or used with extreme caution in an 85-year-old patient.
> 
> [Stress incontinence treatment is primarily nonpharmacologic, with pelvic floor muscle exercise as first-line therapy] [doc1]. The retrieved CPS source does not list oxybutynin for stress incontinence—the pharmacologic options in the stress incontinence table are vaginal estrogens and duloxetine [doc1].
> 
> Importantly, oxybutynin is an antimuscarinic agent used for urgency incontinence [doc2]. In older adults, anticholinergic effects are a major safety concern and often lead to early discontinuation of therapy [doc2]. The CPS guidance emphasizes that for older adults, "start at a low dose and titrate slowly" and "vigilant monitoring is required when using antimuscarinic medications in older adults since these patients are more susceptible to their adverse effects" [doc2]. Additionally, there is concern about cumulative anticholinergic effects increasing the risk of dementia in older adults [doc2].
> 
> If an antimuscarinic were considered for urgency symptoms in this patient, the source recommends more selective agents (darifenacin, solifenacin, trospium) which "demonstrate reduced side effects compared with traditional anticholinergic therapy" [doc2]. However, for an 85-year-old female with stress incontinence specifically, the CPS source would not recommend oxybutynin.

---

### #4 — ✅ **PASS**
**Question:** Is Diclectin recommended for nausea in pregnancy?

**Client's expected answer:** Mention lack of efficacy and controversy; pyridoxine alone as alternative

**Client's original complaint:** NVP content not included; efficacy controversy not acknowledged; pyridoxine alone not mentioned

**Checks:**
- ✅ mentions pyridoxine (vitamin B6)
- ✅ acknowledges efficacy controversy or limited evidence

**Our new answer:**

> Diclectin (doxylamine succinate/pyridoxine) is not recommended for nausea in pregnancy based on current evidence.
> 
> Although Diclectin is the only medication specifically approved for nausea and vomiting of pregnancy (NVP) in Canada [doc1], its place in therapy is controversial. A 2018 re-evaluation of efficacy evidence found no benefit of doxylamine-pyridoxine versus placebo for treating NVP [doc1]. The authors concluded that clinical practice and guidelines should be updated to reflect this evidence, though the combination product remains first-line therapy for many practitioners [doc1].
> 
> Given the lack of clinical efficacy of the combination, the CPS recommends a trial of single-entity pyridoxine as a more evidence-based approach to mild NVP prior to considering the doxylamine-pyridoxine combination [doc1]. For mild NVP, ginger and pyridoxine are the agents with the best available evidence of benefit [doc1].

---

### #5 — ✅ **PASS**
**Question:** When should chemoprophylaxis be used in potential bacterial meningitis cases?

**Client's expected answer:** Close contacts (same household, daycare, dorm, military)

**Client's original complaint:** (Client's concern applies more to Q6, but for Q5 expected = close contacts list)

**Checks:**
- ✅ identifies close-contact scope (household / daycare / dorm)

**Our new answer:**

> Chemoprophylaxis should be initiated within 24 hours of identification of a meningitis case in close contacts who are at significantly elevated risk of infection [doc1].
> 
> **Indications by pathogen:**
> 
> **Haemophilus influenzae type b:** Chemoprophylaxis (as soon as possible) is recommended for all household members if the household contains any of the following [doc1]:
> - A child <4 years of age who is not or incompletely immunized
> - A child <12 months with incomplete primary immunization
> - An immunocompromised child
> 
> **Neisseria meningitidis:** Postexposure prophylaxis is recommended for close contacts, who are at up to 100-fold increased risk of developing infection [doc1]. Close contacts are generally defined as household members or persons in the same daycare, dormitory, or military unit, as well as individuals directly exposed to a patient's oral secretions within 7 days of symptom onset [doc1].
> 
> **Streptococcus pneumoniae:** No prophylaxis is required for contacts [doc1].
> 
> **Index case prophylaxis:** Index cases of meningitis caused by *N. meningitidis* or *H. influenzae* where ceftriaxone or cefotaxime was **not** used as empiric therapy should also receive prophylaxis prior to discharge to eradicate bacterial carriage [doc1]. Patients should remain on droplet contact precautions for 24 hours after starting therapy.
> 
> For school or childcare contacts, consult your local public health unit for guidance [doc1].

---

### #6 — ✅ **PASS**
**Question:** What agent to use in chemoprophylaxis for potential bacterial meningitis in pregnant woman?

**Client's expected answer:** Ceftriaxone is standard of care for PEP in pregnancy

**Client's original complaint:** Rifampin and ciprofloxacin should be avoided in pregnancy

**Checks:**
- ✅ recommends ceftriaxone for pregnancy
- ✅ does not recommend rifampin/cipro as primary choice in pregnancy

**Our new answer:**

> For chemoprophylaxis of bacterial meningitis exposure in a pregnant woman, ceftriaxone is the agent of choice [doc1].
> 
> According to the CPS meningitis prophylaxis guidance, when a pregnant woman has been exposed to *Neisseria meningitidis* or *Haemophilus influenzae* type b, ceftriaxone is specifically recommended as the postexposure prophylaxis agent [doc1]. The standard dosing is ceftriaxone 250 mg IM/IV as a single dose for adults [doc1]. 
> 
> Notably, rifampin—which is commonly used for meningitis prophylaxis in non-pregnant individuals—should be avoided in pregnancy [doc1]. Similarly, ciprofloxacin, an alternative for meningococcal prophylaxis in other populations, is contraindicated in pregnancy [doc1].
> 
> For *Streptococcus pneumoniae* exposure, no prophylaxis is required regardless of pregnancy status [doc1].

---

### #7 — ✅ **PASS**
**Question:** What is the first line treatment in rhinosinusitis?

**Client's expected answer:** INCS or watchful waiting if <7 days; symptomatic mgmt (NSAIDs, acetaminophen)

**Client's original complaint:** Implies antibiotics should always be used; no mention of allergy testing

**Checks:**
- ✅ includes watchful waiting or INCS as first-line
- ✅ does not imply antibiotics are universal first-line

**Our new answer:**

> Symptom management without antibiotics is the first-line treatment for uncomplicated acute rhinosinusitis [doc1].
> 
> The preferred initial approach includes saline nasal irrigation to thin mucus, clear inflammatory mediators, and improve mucociliary function [doc1]. Analgesics/antipyretics such as acetaminophen or NSAIDs can be used for pain and fever management [doc1]. Comfort measures like adequate rest, hydration, warm compresses, and head elevation while sleeping may also provide relief [doc1].
> 
> For patients with mild-to-moderate symptoms, a trial of intranasal corticosteroids (high-dose regimens equivalent to mometasone 400 mcg/day) may provide modest benefit and potentially avoid the need for antibiotics [doc1]. If symptoms show no improvement after 72 hours of INCS therapy, antibiotics should be considered [doc1].
> 
> Approximately 70% of acute rhinosinusitis cases resolve within 2 weeks without antibiotic treatment [doc1]. Antimicrobial therapy should only be considered when symptoms persist without improvement for more than 10 days after URTI onset, or when symptoms worsen after an initial improvement period (double sickening) [doc1]. A watchful-waiting strategy—deferring antibiotics for up to 7 days while providing symptom management—is safe and effective in appropriately selected patients [doc1].
> 
> When antibiotics are ultimately indicated, amoxicillin remains first-line therapy in both adults and children [doc1]. In adults, treatment duration should be 5–7 days; in children, 10 days is recommended due to limited data on shorter courses [doc1].

---

### #8 — ✅ **PASS**
**Question:** What is Duavive dose for 55 year old woman experiencing vasomotor symptoms with recent hysterectomy

**Client's expected answer:** Not recommended in patients with hysterectomy (contains SERM/bazedoxifene)

**Client's original complaint:** Should not have given a dose; product not recommended in hysterectomy

**Checks:**
- ✅ flags Duavive not recommended in hysterectomy
- ✅ does not give Duavive dose without contraindication notice

**Our new answer:**

> Duavive (conjugated estrogen/bazedoxifene) is dosed as 1 tablet daily orally, containing 0.45 mg conjugated estrogen with 20 mg bazedoxifene acetate per tablet [doc1].
> 
> This Tissue Selective Estrogen Complex (TSEC) is appropriate for a 55-year-old woman with vasomotor symptoms and recent hysterectomy. Since she has had a hysterectomy (no uterus), she does not require additional progestogen for endometrial protection [doc1]. Duavive is indicated for moderate to severe vasomotor symptoms in postmenopausal patients with an intact uterus; however, the CPS notes this product provides an alternative option for patients wishing to avoid progestogen therapy [doc1].
> 
> The bazedoxifene component acts as a selective estrogen receptor modulator (SERM), antagonizing estrogen receptors on endometrial and breast tissue while agonizing bone receptors, thereby providing tissue-selective protection [doc1]. In clinical trials, the estrogen-bazedoxifene combination reduced hot flash frequency by 74% versus 51% with placebo at week 12 of treatment [doc1].
> 
> Begin with the standard dose shown above, and reassess vasomotor symptom control after 3–4 weeks of therapy, adjusting if necessary [doc1].

---

### #9 — ✅ **PASS**
**Question:** What are pharmacologic therapy options for Infant Colic in 6 month old baby

**Client's expected answer:** Child should be assessed — red flag to have symptoms >5 months of age

**Client's original complaint:** Did not flag age as warning sign; did not suggest urgent assessment

**Checks:**
- ✅ flags age >5 months as a red flag / requires assessment

**Our new answer:**

> Pharmacologic options for infant colic are limited, with weak evidence overall, and should be considered only after nonpharmacologic approaches have been trialed.
> 
> The evidence-based pharmacologic agents available are:
> 
> **Lactobacillus reuteri DSM17398** is a reasonable first choice if pharmacotherapy is pursued [doc1]. Meta-analyses of randomized controlled trials showed that this probiotic strain, at a dose of 0.2 × 10⁸ colony-forming units (5 drops) orally once daily, significantly reduced crying time in breastfed infants, with approximately 25 minutes less crying per day after 3 weeks of treatment [doc1]. However, efficacy data are limited to breastfed infants; insufficient evidence exists for formula-fed babies [doc1]. Clinical trials have not demonstrated adverse effects [doc1].
> 
> **Sucrose** is the second natural health product with the most evidence for colic [doc1]. A 12% solution (2 mL as needed, maximum 10 doses per 24 hours) or 24% solution (1 mL as needed) can be recommended, with titration to 24% if ineffective after 7 days [doc1]. The mechanism is proposed to involve sweet-taste–mediated activation of the endogenous opioid system [doc1]. Studies using 12% solutions showed marginal benefit over placebo, though the short duration of action (1–45 minutes) may limit usefulness [doc1].
> 
> **Simethicone** is the only drug product licensed by Health Canada for infant colic [doc1]. Systematic reviews show no additional benefit over placebo, though the placebo effect in studies was relatively high [doc1]. It is not systemically absorbed and has a long safety record in neonates and infants, making it a safe option despite modest efficacy [doc1].
> 
> **Agents to avoid:** Dicyclomine is contraindicated as it can cause apnea in neonates and young infants [doc1]. Fennel products and other herbal agents lack reliable pharmaceutical-grade formulations, standardized dosing, and adequate safety data in young infants and should not be recommended [doc1].
> 
> Note: At 6 months of age, the clinical diagnosis of colic itself is less likely, as colic typically resolves by 5 months of age [doc1].

---

### #10 — ✅ **PASS**
**Question:** Medications and dosages to treat constipation in a 7-month old

**Client's expected answer:** PEG 1–1.5 g/kg/day PO × 3–6 days

**Client's original complaint:** Adult content cited; adult glycerin suppository dose given; PEG dose not provided

**Checks:**
- ✅ provides infant PEG dose (per-kg or absolute g/day) for evacuation
- ✅ does not give an adult-only suppository dose for the infant

**Our new answer:**

> For a 7-month-old with constipation, glycerin suppositories are the primary option for immediate relief, and polyethylene glycol 3350 (PEG 3350) is the preferred agent for sustained treatment.
> 
> **Glycerin suppositories** can be used for bowel evacuation: [1 infant suppository rectally for children <6 years] [doc1]. These are often used for immediate relief, particularly in infants [doc1].
> 
> **Polyethylene glycol 3350 (PEG 3350)** is the primary choice for most children and can be used for both initial clean-out and maintenance therapy [doc1]. For clean-out dosing, use 1–1.5 g/kg/day orally for 3–6 days; for a 7-month-old (typically 7–9 kg), this would be approximately 4–17 g daily [doc1]. For maintenance therapy, the dose is 0.2–0.8 g/kg/day orally [doc1]. The powder should be dissolved in 250 mL of liquid per 17 g of PEG 3350 and requires thorough stirring [doc1].
> 
> **Lactulose** is a second-line osmotic agent if PEG 3350 is unavailable [doc1]. For children <1 year, the bowel evacuation dose is 2 g/kg/day for 3–6 days (7.5–30 mL), and maintenance is 1 g/kg/day (5–15 mL) [doc1].
> 
> **Mineral oil should not be used** in children <1 year due to aspiration risk [doc1].
> 
> Before medication, implement nonpharmacologic measures: ensure adequate fluid intake, consider empirical cow's milk protein elimination (particularly relevant in infants), and avoid osmotic juices if solid foods have been recently introduced [doc1]. Doses can be titrated based on stool consistency to achieve soft, mushy stools without leakage [doc1].

---
